Shares of Jubilant Life Sciences surged 10.4 per cent in early trade to its highest since October 28. The company has obtained approval from US FDA for two key drugs.
These approvals will act as medium-term positive for the stock, say traders.
Jubilant Life Sciences is up 7%, has received approvals for Mycophenolate Mofetil, an immuno-suppressant, and Rizatriptan from US FDA
— Rajalakshmi Nirmal (@crajalakshmic)
January 6, 2015At 10.30 am, the stock was up Rs 10.60 or 7.59 per cent at Rs 150.30 on the BSE.